Evaxion Biotech expands R&D pipeline with new vaccine program

Evaxion initiates work to develop a new preventive vaccine against Group A Streptococcus, a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis and less severe yet serious diseases like strep throat and scarlet fever. The new vaccine program, named EVX-B4, has been added to Evaxion’s research & development pipeline of cancer and infectious disease vaccine candidates. Initial computational analysis demonstrated that AI-Immunology can identify novel vaccine targets to combat GAS, which could pave the way for a new approach to fight the bacteria. Deploying AI-Immunology allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4. This work will create a comprehensive preclinical data package to facilitate partnership discussions.